Juxtamembrane Mutant V560GKit Is More Sensitive to Imatinib (STI571) Compared with Wild-Type c-Kit Whereas the Kinase Domain Mutant D816VKit Is Resistant
Supported by a grant from the National Health and Medical Research Council of Australia (NHMRC). M. F. is recipient of an Australian Postgraduate Award. L. K. A. is a NHMRC Principal Research Fellow. Imatinib was provided by Novartis.